Therefore, Triciribine and Rapamycin, as inhibitors of the AKT/mTOR pathway, may be further studied for their potential use as adjunct therapy in the treatment of neuroblastoma and glioblastoma, given their in vitro ability to successfully inhibit and eradicate an enriched population of CSC. The gene discussed is AKT1; the disease is neuroblastoma.